Brokerages expect that Radius Health, Inc. (NASDAQ:RDUS) will report $6.87 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Radius Health’s earnings, with the lowest sales estimate coming in at $6.39 million and the highest estimate coming in at $7.35 million. The business is expected to announce its next earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Radius Health will report full-year sales of $6.87 million for the current year, with estimates ranging from $20.84 million to $21.79 million. For the next financial year, analysts anticipate that the firm will report sales of $77.47 million per share, with estimates ranging from $60.85 million to $94.08 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Radius Health.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter last year, the company earned ($1.07) EPS.

RDUS has been the topic of several recent analyst reports. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, July 17th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Jefferies Group LLC restated a “hold” rating and issued a $38.00 target price (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Finally, BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Radius Health presently has a consensus rating of “Hold” and an average price target of $51.00.

ILLEGAL ACTIVITY NOTICE: “$6.87 Million in Sales Expected for Radius Health, Inc. (RDUS) This Quarter” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/13/6-87-million-in-sales-expected-for-radius-health-inc-rdus-this-quarter.html.

Shares of Radius Health (NASDAQ RDUS) traded down $0.30 during trading on Monday, hitting $28.10. 1,288,900 shares of the stock traded hands, compared to its average volume of 1,193,185. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health has a 1 year low of $27.16 and a 1 year high of $55.97.

In other Radius Health news, VP Brent Hatzis-Schoch acquired 1,778 shares of Radius Health stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares of the company’s stock, valued at $63,989.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of Radius Health stock in a transaction that occurred on Thursday, September 14th. The stock was acquired at an average price of $33.45 per share, with a total value of $5,017,500.00. Following the completion of the acquisition, the insider now directly owns 5,448,799 shares in the company, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. Insiders purchased a total of 427,678 shares of company stock valued at $14,430,298 over the last quarter. 15.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BB Biotech AG increased its holdings in Radius Health by 11.0% in the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after buying an additional 498,400 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Radius Health by 18.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after purchasing an additional 569,300 shares during the period. Vanguard Group Inc. grew its stake in shares of Radius Health by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after purchasing an additional 135,071 shares during the period. BlackRock Inc. grew its stake in shares of Radius Health by 10.0% during the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after purchasing an additional 262,896 shares during the period. Finally, State Street Corp grew its stake in shares of Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after purchasing an additional 213,399 shares during the period.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.